产品图片
货号/SKU
NR-46422
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、2
产品描述信息
NR-46422??Staphylococcus aureus, AID 1001123(Bacteria)|Staphylococcus aureus|AID 1001123|-60°C or colder|B LimbagoAcknowledgment for publications should read "The following reagent was provided by the Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) for distribution by BEI Resources, NIAID, NIH: Staphylococcus aureus, Strain AID 1001123, NR-46422."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
Staphylococcus aureus (S. aureus), strain AID 1001123 (also referred to as VRSA-11b and VRS11b) was isolated in 2010 in Delaware, USA from wound drainage of a 63-year-old female with a prosthetic joint infection who had been unsuccessfully treated with continuous vancomycin therapy for 3 months. AID 1001123 is a co-isolate with AIS 1001095 (VRS11a) from the same patient and they were isolated at the same time. Both are mecA positive but unlike AIS 1001095, AID 1001123 is phenotypically resistant to oxacillin by the cefoxitin disk diffusion test.
S. aureus, strain AID 1001123 is a vancomycin-resistant S. aureus (VRSA) strain. S. aureus, strain AID 1001123 was deposited as positive for mecA and vanA; negative for vanB, PVL and arginine catabolic mobile element (ACME); pulsed-field type USA100; spa repeats TJMBMDMGMK; Ridom spa type t002. S. aureus, strain AID 1001123 is a USA100 isolate. USA100 isolates have the same MLST profile (ST 5) and SCCmec (subtype II) and are usually resistant to erythromycin and spectinomycin as well as being multiresistant to other commonly used therapeutic agents. USA100 is the most prevalent U.S health care-associated pulsed-field type and is endemic in many U.S. hospitals. S. aureus, strain AID 1001123 is constitutively resistant to vancomycin due to a mutation in vanR, which regulates the expression of the vanA operon. It has a second mutation in D-alanyl:D-alanine ligase (Ddl), an enzyme involved in biosynthesis of peptidoglycans. The presence of the vanA operon compensates for the Ddl mutation by providing alternative peptidoglycans for cell wall synthesis; however, some have found that the change in the type of peptidoglycans produced renders S. aureus, strain AID 1001123 susceptible to oxacillin. The complete genome sequence of S. aureus, strain AID 1001123 is available (GenBank: AHBV00000000).
Each vial contains approximately 0.5 mL of bacterial culture in Brain Heart Infusion broth supplemented with 6 ?g/mL vancomycin and 10% glycerol.
Staphylococcus aureus (S. aureus), strain AID 1001123 (also referred to as VRSA-11b and VRS11b) was isolated in 2010 in Delaware, USA from wound drainage of a 63-year-old female with a prosthetic joint infection who had been unsuccessfully treated with continuous vancomycin therapy for 3 months. AID 1001123 is a co-isolate with AIS 1001095 (VRS11a) from the same patient and they were isolated at the same time. Both are mecA positive but unlike AIS 1001095, AID 1001123 is phenotypically resistant to oxacillin by the cefoxitin disk diffusion test.
S. aureus, strain AID 1001123 is a vancomycin-resistant S. aureus (VRSA) strain. S. aureus, strain AID 1001123 was deposited as positive for mecA and vanA; negative for vanB, PVL and arginine catabolic mobile element (ACME); pulsed-field type USA100; spa repeats TJMBMDMGMK; Ridom spa type t002. S. aureus, strain AID 1001123 is a USA100 isolate. USA100 isolates have the same MLST profile (ST 5) and SCCmec (subtype II) and are usually resistant to erythromycin and spectinomycin as well as being multiresistant to other commonly used therapeutic agents. USA100 is the most prevalent U.S health care-associated pulsed-field type and is endemic in many U.S. hospitals. S. aureus, strain AID 1001123 is constitutively resistant to vancomycin due to a mutation in vanR, which regulates the expression of the vanA operon. It has a second mutation in D-alanyl:D-alanine ligase (Ddl), an enzyme involved in biosynthesis of peptidoglycans. The presence of the vanA operon compensates for the Ddl mutation by providing alternative peptidoglycans for cell wall synthesis; however, some have found that the change in the type of peptidoglycans produced renders S. aureus, strain AID 1001123 susceptible to oxacillin. The complete genome sequence of S. aureus, strain AID 1001123 is available (GenBank: AHBV00000000).
Each vial contains approximately 0.5 mL of bacterial culture in Brain Heart Infusion broth supplemented with 6 ?g/mL vancomycin and 10% glycerol.
主要内容
此项目的每个订单数量限制为1.此项目每年可订购两次.通过此限制的订单将在发货前发送到NIAID进行批准. 金黄色葡萄球菌（金黄色葡萄球菌），应变辅助1001123（也称为VRSA-11B和VRS11B）于2010年在美国公开的2010年孤立，来自一名63岁女性的伤口排水，具有假期的关节感染，持续治疗连续的万古霉素治疗3个月.辅助1001123是来自同一患者的AIS 1001095（VRS11a）的共同分离物，同时分离它们.两者都是阳性但与AIS 1001095不同，辅助1001123通过食物蛋白盘扩散试验对牛奶蛋白进行表型抗性. . AUREUS ，应变助剂1001123是一种抗万古霉素的抗性.金黄色葡萄球菌（VRSA）应变. s. AUREUS ，应变助剂1001123沉积为阳性的 MECA 和 vana ;对于 VanB ，PVL和精氨酸分解代谢移动元件（ACME）是阴性的;脉冲场型USA100; spa 重复tjmbmdmgmk; ridom spa 型T002. s. AUREUS ，应变助剂1001123是USA100分离物. USA100分离株具有相同的MLST型谱（ST 5）和SCC MEC （亚型II），并且通常耐红霉素和北霉素以及多霉素与其他常用的治疗剂. USA100是最普遍的美国医疗保健相关的脉冲场类型，在许多美国医院的地方是流行的. s. AUREUS ，应变助剂1001123由于 VANR 的突变而构成抗功霉素，其调节了 vana 操纵子的表达.它具有D-丙基：D-丙氨酸连接酶（DDL）的第二个突变，该酶参与肽聚糖的生物合成.通过提供用于细胞壁合成的替代肽聚糖来补偿DDL突变的 vana 的存在;然而，有些人发现肽聚糖类型的变化产生的蛋黄酱. AUREUS ，应变辅助1001123易患恶酸碱. s的完整基因组序列. AUREUS ，应变助剂1001123可用（Genbank：）. 每个小瓶含有大约0.5ml的脑心输注肉汤中的细菌培养，其补充有6μg/ ml万古霉素和10％甘油.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-04-01
2024-08-18
2022-04-01
2021-12-21
2022-04-01
2020-08-04
2024-05-12
2024-11-06
2022-01-10
2022-04-01
2022-04-01
2022-04-01
2022-04-01